EHA Library - The official digital education library of European Hematology Association (EHA)

Abstract: P523

Title: THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD


Abstract Type: Poster Presentation

Keywords: Outcome | Acute myeloid leukemia | Venetoclax | Clinical trial
This abstract is embargoed until Friday, June 9, 2023 (09:00 CEST)

Presentation during EHA2023: All (e)Poster presentations will be made available as of Friday, June 9, 2023 (09:00 CEST) and will be accessible for on-demand viewing until Tuesday, August 15, 2023 on the Congress platform.


Abstract: P523

Title: THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD


Abstract Type: Poster Presentation

Keywords: Outcome | Acute myeloid leukemia | Venetoclax | Clinical trial
This abstract is embargoed until Friday, June 9, 2023 (09:00 CEST)

Presentation during EHA2023: All (e)Poster presentations will be made available as of Friday, June 9, 2023 (09:00 CEST) and will be accessible for on-demand viewing until Tuesday, August 15, 2023 on the Congress platform.


Abstract: P523

Title: THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD


Abstract Type: Poster Presentation

Keywords: Outcome | Acute myeloid leukemia | Venetoclax | Clinical trial
THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD
Alfonso Piciocchi
Alfonso Piciocchi
Author(s): Alfonso Piciocchi,  
Alfonso Piciocchi
Affiliations:
GIMEMA Foundation, Rome, Italy
Giovanni Marconi,  
Giovanni Marconi
Affiliations:
Hematology Unit, IRCCS Istituto Romagnolo Per Lo Studio Dei Tumori (IRST) "Dino Amadori, Meldola, Italy
Marta Cipriani,  
Marta Cipriani
Affiliations:
Sapienza University, Rome, Italy; GIMEMA Foundation, Rome, Italy
Monica Messina,  
Monica Messina
Affiliations:
GIMEMA Foundation, Rome, Italy
Fabio Guolo,  
Fabio Guolo
Affiliations:
Department of Internal Medicine (Di.M.I.) University of Genoa, Genoa, Italy
Paola Minetto,  
Paola Minetto
Affiliations:
Department of Internal Medicine (Di.M.I.) University of Genoa, Genoa, Italy
Francesca Paoloni,  
Francesca Paoloni
Affiliations:
GIMEMA Foundation, Rome, Italy
Francesca Cotugno,  
Francesca Cotugno
Affiliations:
GIMEMA Foundation, Rome, Italy
Laura Di Donato,  
Laura Di Donato
Affiliations:
GIMEMA Foundation, Rome, Italy
Giorgia Simonetti,  
Giorgia Simonetti
Affiliations:
Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori",, Meldola, Italy
Raffaele Palmieri,  
Raffaele Palmieri
Affiliations:
Division of Hematology, Tor Vergata Foundation Polyclinic, Rome, Italy; Hematology, Department of Biomedicine e Prevention, Tor Vergata University, Rome, Italy
Francesco Buccisano,  
Francesco Buccisano
Affiliations:
Division of Hematology, Tor Vergata Foundation Polyclinic, Rome, Italy; Hematology, Department of Biomedicine e Prevention, Tor Vergata University, Rome, Italy
Paola Fazi,  
Paola Fazi
Affiliations:
GIMEMA Foundation, Rome, Italy
Marco Vignetti,  
Marco Vignetti
Affiliations:
GIMEMA Foundation, Rome, Italy
Roberto M. Lemoni,  
Roberto M. Lemoni
Affiliations:
Department of Internal Medicine (Di.M.I.) University of Genoa, Genoa, Italy
Adriano Venditti,  
Adriano Venditti
Affiliations:
Division of Hematology, Tor Vergata Foundation Polyclinic, Rome, Italy; Hematology, Department of Biomedicine e Prevention, Tor Vergata University, Rome, Italy
Giovanni Martinelli
Giovanni Martinelli
Affiliations:
IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy
(Abstract release date: 05/11/23) EHA Library. Piciocchi A. 06/08/2023; 386352; P523
Abstract: P523

Title: THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD


Abstract Type: Poster Presentation

Keywords: Outcome | Acute myeloid leukemia | Venetoclax | Clinical trial
This abstract is embargoed until Friday, June 9, 2023 (09:00 CEST)

Presentation during EHA2023: All (e)Poster presentations will be made available as of Friday, June 9, 2023 (09:00 CEST) and will be accessible for on-demand viewing until Tuesday, August 15, 2023 on the Congress platform.


Abstract: P523

Title: THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD


Abstract Type: Poster Presentation

Keywords: Outcome | Acute myeloid leukemia | Venetoclax | Clinical trial
This abstract is embargoed until Friday, June 9, 2023 (09:00 CEST)

Presentation during EHA2023: All (e)Poster presentations will be made available as of Friday, June 9, 2023 (09:00 CEST) and will be accessible for on-demand viewing until Tuesday, August 15, 2023 on the Congress platform.


Abstract: P523

Title: THE COMPARISON OF VFLAI, FLAI AND 3+7 REGIMENS BY MULTILEVEL PROPENSITY SCORE WEIGHTING HIGHLIGHTS THE BENEFIT OF THE ADDITION OF VENETOCLAX IN NO LOW-RISK AML TREATED IN GIMEMA TRIALS AND REAL WORLD


Abstract Type: Poster Presentation

Keywords: Outcome | Acute myeloid leukemia | Venetoclax | Clinical trial

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies